9WV.F NUTRIBAND INC. DL -001

Healthcare Biotechnology Frankfurt Exchange
5.20 EUR
Close of Nov 11, 2026
2.12 8.20
Market cap
EUR 63.2M
P/E
-
P/B
12.76x
ROE
-79.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jul 2026.

Is 9WV.F undervalued?

Graham number

The Graham number of NUTRIBAND INC. DL -001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NUTRIBAND INC. DL -001 fundamental analysis

No fundamental analysis for NUTRIBAND INC. DL -001 yet.

NUTRIBAND INC. DL -001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NUTRIBAND INC. DL -001

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Full company profile